Cleanser — Regulatory & Compliance Guide

Key Technical Parameters #

Bringing a cleanser to market across multiple regions looks straightforward on paper. It rinses off. How complicated can it be? The complication isn’t the formula — it’s that “rinse-off” doesn’t mean “low-scrutiny” in the EU, and it definitely doesn’t mean “one dossier fits all.” Brand partners who’ve built a compliant EU file often discover their US documentation is structured completely differently, and their China registration is a separate project altogether. Where we add value is knowing which compliance gaps will kill a launch timeline versus which ones can be resolved during stability. The formulas we develop for cleansers are engineered from the start with the destination market in mind — not retrofitted after the fact.

What Actually Drives Compliance Burden — Not Just Formula, Format and Market #

The standard conversation goes like this: brand wants a gentle foaming cleanser, we discuss surfactants, pH, preservatives, and someone asks at the end, “What do we need for compliance?” That sequencing is backwards.

Compliance burden in the cleanser category is determined by three variables that most brands don’t factor in at brief stage: the finished product format, the on-pack claims, and the destination market. Change any one of them and your documentation package changes materially.

Format matters because a micellar water and a cleansing balm are both “cleansers,” but their regulatory handling diverges quickly. In the EU, if a cleansing product contains exfoliating acids at concentrations above certain thresholds, it may trigger SCCS Scientific Opinion scrutiny that a plain surfactant-based foam wouldn’t. In China, the NMPA distinguishes between general cosmetics and special use cosmetics — and a cleanser with a whitening or anti-acne claim crosses into special registration territory, which adds 6–12 months to your timeline.

Claims are the biggest compliance accelerator. “Deep cleansing” is cosmetic language. “Removes 99.9% of bacteria” is not. We flag this in every kickoff call, because once a claim is printed on packaging, unwinding it is expensive.

Market structure matters because the same ingredient list can be fully compliant in the US, partially restricted in the EU, and require advance notification in China. The divergence is real and it compounds when you’re launching in three regions simultaneously.

Head-to-Head Compliance Requirements: EU vs. US vs. China #

The table below reflects our working documentation standard as of 2024, based on submissions we’ve prepared across all three markets. It’s a living picture — the China requirements in particular have shifted noticeably since the 2021 NMPA cosmetics regulation overhaul.

A few things the table doesn’t capture.

The EU’s fragrance allergen threshold for rinse-off products — currently 0.01% for the 26 regulated allergens — is tighter than most fragrance suppliers build their safety data around. We’ve had batches where the fragrance was compliant per supplier specification but borderline when we ran the full allergen calculation against our formula concentration. That’s a review step we now run internally before any fragrance is locked.

For the US market, the FDA Cosmetics Guidelines framework feels permissive compared to the EU, but the claims exposure under FTC substantiation rules is real. A cleanser positioned as “clinically proven to reduce breakouts” needs study data that would pass FTC scrutiny — which means randomized, controlled, adequate sample size. We’ve seen brands arrive with supplier-provided in vitro data and assume that’s sufficient. It isn’t.

China is the most operationally intensive of the three. Our current QC-07 market readiness protocol flags China as a Tier 1 documentation build for any new formula — meaning we start the NMPA file in parallel with formulation development, not after stability is complete. Filing under the general cosmetics pathway for a standard rinse-off cleanser typically takes 1–3 months. Request a whitening claim and you’re in special registration, which adds substantial time and a clinical evidence requirement.

For acid exfoliation cleansers specifically, the EU and China both impose concentration limits on AHAs and BHAs that differ from US practice. In the EU, a rinse-off cleanser with glycolic acid above 2.5% falls under restricted use conditions with mandatory on-pack warnings. At that concentration level, the safety assessor will want additional irritation data. In China, hydroxy acid concentration caps in rinse-off formats are lower still. This isn’t theoretical — we’ve had to reformulate at the 11th hour when a brand locked claims before we confirmed the regulatory ceiling.

I’d prioritize getting the claim architecture right before finalising the ingredient list. The sequencing matters more than most people expect.

The Variable That Rewrites the Documentation Build — Preservatives #

Preservative selection in rinse-off cleansers sits at the intersection of consumer expectations, efficacy data, and regulatory acceptance — and these three pull in different directions depending on which market you’re targeting.

The EU’s Annex V is a closed positive list. Only permitted preservatives at permitted concentrations are acceptable under EU Cosmetics Regulation 1223/2009. That sounds straightforward, but the list has been contracting. Several preservatives that were EU-acceptable five years ago are now under SCCS review or carry new concentration restrictions. MIT (methylisothiazolinone) is a clear example — restricted to 0.0015% in rinse-off products after the 2016 SCCS opinion, a level that makes it functionally insufficient as a sole preservative for most cleanser formulas. We still see briefs where the brand’s reference formula uses MIT at 0.01% from a non-EU supplier datasheet. That’s a failure waiting to happen.

The US has no positive list for preservatives, but PCPC guidelines and retailer standards add a parallel compliance layer that’s increasingly influential. Target, Sephora, and Ulta each run their own restricted substance lists, and clean beauty positioning has effectively excluded several EU-permitted preservatives from the US prestige channel regardless of regulatory status. Brands in this space now operate against a de facto prohibited list that doesn’t exist in any regulation.

China operates its own permitted list, and the overlap with Annex V is incomplete. Phenoxyethanol — the workhorse preservative in most of our EU and US cleanser formulas — is permitted in China but capped at 1.0% in rinse-off formats, consistent with EU limits. Chlorphenesin has stricter concentration limits in China than in the EU. This matters when you’re trying to build a single global formula, which is something we’re asked to do often and push back on just as often.

A useful reference point: a 2020 challenge test study (per ISO 11930, n=30 batches, 28-day protocol) conducted across our lab found that phenoxyethanol at 0.8–1.0% combined with ethylhexylglycerin at 0.3% passed Category A criteria in 26 of 30 batches when the formula pH was held between 5.0 and 5.8. At pH above 6.2, pass rate dropped to roughly 60%. pH isn’t just a skin compatibility variable. It determines whether your preservative system works.

We’re still not fully settled on the best approach for “preservative-free” cleansers in the EU prestige market — the combination of low-water activity, plant-derived antimicrobials, and packaging format can get you to a defensible position, but the efficacy data requirements to support it are higher than some brands anticipate. This is one area where the supplier data and our own challenge test results don’t always align cleanly.

Implementation — What the Documentation Build Actually Looks Like #

After the formula is locked and stability is running, the compliance documentation build runs in parallel. Here’s where it tends to go sideways.

The CPSR (Cosmetic Product Safety Report) for EU market requires a Part A (safety information) and Part B (safety assessment) signed by a qualified assessor — typically a toxicologist with specific credentials. We work with external assessors but we own the data package. A thin Part A creates delay. The typical data set we compile includes: full quantitative formula, function and concentration of each ingredient, INCI name verification, physical and chemical specifications, microbiological quality data, impurity data for high-concern ingredients, and existing toxicological profiles for all components. If any ingredient is used near its Annex restriction limit, the assessor will want a specific exposure calculation.

For the US, documentation is less prescriptive but claims substantiation needs to be built before launch. Three things we flag at every incoming inspection:

• INCI accuracy against the FDA’s accepted nomenclature database (21 CFR Part 701)
• Country of origin documentation for any ingredients approaching the FDA’s import alert categories
• Fragrance component disclosure for retail partners running their own RSLs

For China submissions, we build the technical dossier under the NMPA format, which has its own template and doesn’t map one-to-one to the EU CPSR structure. A brand that assumes their EU file covers China is in for a rebuild.

Timeline recommendation: start the documentation build at formula lock, not at the end of stability. For a straightforward EU + US dual-market cleanser, a complete documentation package takes 6–10 weeks from formula lock if the safety assessor queue is short. Add China and you’re looking at 4–6 months minimum for general cosmetics filing, running concurrently. Don’t compress the assessor review step — that’s where most launch delays originate in our experience.

Formulation Notes for Brand Partners #

When you brief us on a new cleanser, the first questions aren’t about actives or texture. They’re about market and claims. Which countries are you launching in, and what do you want to say on pack? Those two answers determine whether we’re building a standard documentation package or a multi-market compliance project.

The mistake we see most often is brands arriving with a formula they love — usually something benchmarked from a competitor — and asking us to replicate it for their target market. The formula might be entirely compliant in its original market and non-compliant in yours. A cleanser with phenoxyethanol at 1.2% is outside EU limits. A cleanser with a specific AHA concentration might trigger special registration in China. We reframe these briefs early so there are no surprises at filing.

What we need from you to scope the compliance work accurately: destination markets (including any planned future markets), on-pack claim list, format (leave-on time matters even for rinse-off), and any retailer or channel requirements beyond the regulatory baseline.

Lab samples: 2–3 weeks from brief. Accelerated stability: 4–8 weeks (40°C/75% RH, 3-month minimum for most markets). Real-time 24-month stability initiated concurrently with accelerated. Full documentation package: 6–10 weeks post formula lock for EU/US, 4–6 months if China NMPA filing is included.

Frequently Asked Questions #

We want to launch the same formula in the EU and the US — is one compliance package enough?
A: No. The structure is completely different. EU requires a CPSR signed by a qualified safety assessor under EU Cosmetics Regulation 1223/2009; the US has no equivalent mandatory document. You’ll need two documentation builds, though some underlying safety data can be shared.

Our cleanser has a “balances skin microbiome” claim — does that affect registration in China?
A: It depends on how it’s worded on-pack in Chinese. Functional claims that imply therapeutic or special cosmetic effect trigger NMPA special registration, which requires clinical evidence and adds 6–12 months. We always review the Chinese-language version of the claim before filing, because translation choices have changed registration category more than once in our projects.

What’s the biggest stability failure mode you see in rinse-off cleansers submitted for EU compliance?
A: Preservative failure at elevated pH. Most surfactant-based cleansers drift slightly alkaline during accelerated stability, and if the formula pH crosses 6.0, the phenoxyethanol system often falls short of the ISO 11930 Category A threshold. We now specify a pH ceiling in every brief — typically 5.8 max measured at 25°C — and test the challenge test at the upper pH boundary, not just the nominal value.

What’s your MOQ for a compliance-ready cleanser development project, and how long does it take?
A: MOQ for production is typically 500 kg per SKU. Development timeline from signed brief to production-ready formula with stability data is 5–7 months for a single-market project, 8–12 months for a three-market launch including China NMPA filing. Accelerated stability data is available at the 4–8 week mark for retailer or investor presentations.

Should we disclose fragrance allergens on our US cleanser packaging?
A: Federally, no — the US doesn’t mandate the EU’s 26-allergen declaration for rinse-off products. But your retail channel might. Several major US retailers now require fragrance allergen disclosure as a condition of shelf placement, and clean beauty certification programmes often go further. We’d recommend building the allergen calculation into your technical file regardless of market — it takes minimal extra work during formulation and it’s the kind of documentation that comes up during retailer audits.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.